
OCS Stock Forecast & Price Target
OCS Analyst Ratings
Bulls say
Oculis Holding is expected to see success due to its strong cash position of $278 million, which is expected to fund operations into the second half of 2029, and the company's focus on late-stage development programs Privosegtor and Licaminlimab, which have blockbuster potential in addressing optic neuropathies. However, risks to their target price include clinical trial failure, competition with other late-stage development candidates, commercialization risk, and financial risk, as the company will require additional capital for the development and potential commercialization of its product candidates.
Bears say
Oculis Holding is facing a negative outlook as its Phase III trials for OCS-01 eye drops in diabetic macular edema (DME) missed their primary and key secondary endpoints. Despite a strong balance sheet and promising late-stage programs, the company's decision to not pursue an FDA regulatory filing for OCS-01 in DME and redirect resources to other programs raises concerns about its ability to successfully bring new products to market. Additionally, while its Privosegtor program shows potential in the neuro-ophthalic market, it may face challenges in obtaining adequate payor access and reimbursement.
This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.
OCS Analyst Forecast & Price Prediction
Start investing in OCS
Order type
Buy in
Order amount
Est. shares
0 shares